Get the Stockscreener App
414.87
1.82%
7.43
After Hours:
415.01
0.14
+0.03%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $414.87, with a volume of 2.01M.
It is up +1.82% in the last 24 hours and up +6.03% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$407.44
Open:
$405
24h Volume:
2.01M
Relative Volume:
0.74
Market Cap:
$224.29B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
28.85
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.94%
1M Performance:
+6.03%
6M Performance:
+16.67%
1Y Performance:
+40.43%
1-Day Range:
$404.05
$417.78
1-Week Range:
$396.01
$417.78
52-Week Range:
$288.00
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
414.87 | 224.29B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-05-26 | Reiterated | BMO Capital Markets | Outperform |
| Aug-05-26 | Reiterated | BofA Securities | Underperform |
| Aug-05-26 | Reiterated | Canaccord Genuity | Hold |
| Aug-05-26 | Reiterated | Morgan Stanley | Equal-Weight |
| Aug-05-26 | Reiterated | Oppenheimer | Outperform |
| Aug-05-26 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-05-26 | Reiterated | Robert W. Baird | Underperform |
| Aug-05-26 | Reiterated | Truist | Hold |
| Aug-05-26 | Reiterated | Wells Fargo | Equal Weight |
| May-05-26 | Downgrade | Erste Group | Buy → Hold |
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Can Amgen (NASDAQ:AMGN) Win With Direct-to-Patient Access Programs? - Kalkine Media
3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC - MarketBeat
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc. - MarketBeat
2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC - MarketBeat
AMGEN INC. R (AMG.MU) Q2 FY2026 earnings call transcript - Yahoo Finance
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com - Investing.com India
Is AMGN Overvalued? DCF Says Worth $189 - GuruFocus
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) Interactive Stock Chart - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Sold by CX Institutional - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock - benzinga.com
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript - GuruFocus
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know - TradingKey
Amgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overval - GuruFocus
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
More Than Skin Deep: Understanding Discoid Lupus Erythematosus - Amgen
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight - GlobeNewswire Inc.
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial - insights.citeline.com
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - marketwatch.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines - kalkine.ca
Amgen Inc Agencies, 2017 - OpenSecrets
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's - Kalkine Media
AMGN Maintains Rating by Scotiabank -- Price Target Raised to $5 - GuruFocus
Scotiabank maintains Sector Outperform rating on Amgen, $500 price target - tradingview.com
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - Yahoo Finance
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - 24/7 Wall St.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? - Yahoo Finance
Amgen (AMGN), What Is Behind The Fresh Attention? - Yahoo Finance
News | Amgen’s sale-leaseback with Mesirow ranks among largest recent office deals in Chicago suburbs - CoStar
Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook - TradingKey
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus - TradingView
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus - Yahoo Finance
AMGN DCF Analysis: Intrinsic Value $189 vs Price $415 - GuruFocus
Amgen Inc Agencies, 2004 - OpenSecrets
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
| Khosla Rachna | Officer |
Aug 13 '26 |
Proposed Sale |
412.76 |
1,252 |
516,775 |
0 |
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | Officer |
Aug 11 '26 |
Proposed Sale |
414.21 |
2,000 |
828,420 |
0 |
| Derek Miller | Officer |
Aug 06 '26 |
Proposed Sale |
404.85 |
3,890 |
1,574,866 |
0 |
| Grygiel Nancy A. | Officer |
Aug 06 '26 |
Proposed Sale |
447.17 |
2,670 |
1,193,940 |
0 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
0.26%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):